Lacidipine potently augmented the anti‐tumor effects of chemotherapeutic agents on breast cancer in vivo by activating CD45+CD8+ effector T cells and incapacitating CD4+CD25+Foxp3+ Tregs. This evidence concerns the gene CD8A and breast carcinoma.